Lumella test for detection of pre-eclampsia

  • Research type

    Research Study

  • Full title

    Comparison of Glycosylated Fibronectin Test (Lumella®) with sFLT/PLGF ratio test for Assessment of Pre-eclampsia

  • IRAS ID

    329734

  • Contact name

    Amarnath Bhide

  • Contact email

    abhide@sgul.ac.uk

  • Sponsor organisation

    Advanced Global Health Limited

  • Clinicaltrials.gov Identifier

    329734, IRAS Id

  • Duration of Study in the UK

    1 years, 8 months, 31 days

  • Research summary

    Preeclampsia is a condition affecting 5% of pregnancies, characterised by raised blood pressure and presence of protein in urine. It can result in complications affecting mother with organ failure and is a recognised cause of maternal mortality. It can also result in early delivery which expose baby to short- and long-term complications. Early detection and management improve outcomes and reduce associated risks.
    Preeclampsia is associated with increased levels of certain markers in maternal blood. Currently, a test of maternal blood (PlGF/sFlt ratio) is used in NHS to assess risk of developing preeclampsia in suspected cases.
    In this study, we will be examining a new test (Lumella) to compare its performance to standard test.
    Lumella uses pin prick of blood to provide a bedside result for preeclampsia risk in 10 minutes. It is proposed to replace current test that requires blood sample to be sent to laboratory, meaning longer wait for results, delaying treatment.
    We plan to conduct this study in 3 hospitals: St George’s, Epsom and St Helier’s NHS trust. We will offer participation in the study to cases with suspected preeclampsia based on clinical and medical history criteria. In regular settings those cases would be offered current screening test (PlGF/sFlt ratio). Upon discussion with research team and written consent, Lumella test will be performed. Finger prick blood sample will be collected and tested by research team; results will not be shared with neither the participant nor the clinical team.
    The treatment and care of participants will be still based on standard test. We will invite participants to 2 further visits in 2 and 4 weeks, if not delivered earlier, repeat Lumella test and PlGF/sFlt ratio will be performed.
    Anonymous data about pregnancy, delivery and neonatal outcomes will be collected to be able to compare performance of both tests.

  • REC name

    London - Harrow Research Ethics Committee

  • REC reference

    23/PR/0960

  • Date of REC Opinion

    13 Oct 2023

  • REC opinion

    Further Information Favourable Opinion